Search Results for "Membership Participate teams"

ONS Hosts Safe Handling Meeting

ONS Hosts Safe Handling Meeting
Thursday, February 26, 2015

The Oncology Nursing Society (ONS) hosted a meeting of Safe Handling of Hazardous Drugs Association Stakeholders where organizational representatives voiced the concerns of their members about safe handling.

story and image

ONS hosted 14 nurses and association professionals at a Safe Handling of Hazardous Drugs Association Stakeholders meeting on February 16, 2015, at the Paul Hastings, LLP office in Washington, DC. Representatives from five professional organizations participated with ONS members and staff to generate discussion on the issues surrounding safe handling of hazardous drugs.

The objectives for the meeting were to outline key issues in the implementation of standards followed in the safe handling of hazardous drugs, and to provide consensus recommendations regarding the implementation of the U.S. Pharmacopeial Convention's General Chapter 800 Hazardous Drugs–Handling in Healthcare Settings.

Meeting Outcomes

The meeting provided the opportunity for organizational representatives to voice the concerns of their membership regarding safe handling. Presentations and discussions reviewed the literature available and member concerns regarding engineering controls, personal protective equipment (PPE), medical surveillance, attitudes, beliefs, and financial concerns. During this discussion, common ground was identified and summarized in the following consensus statements.

This group agreed that it will

  • Create and continuously promote a culture of patient and healthcare safety.
  • Provide resources, including templates, to promote compliance with implementing safe handling.
  • Reach a consensus on critical definitions (e.g., what defines a spill).
  • Include practitioner input in facility design.
  • Develop resources for how to choose PPE and closed-system transfer devices.
  • Include worker safety standards in the next iteration of chemotherapy and biotherapy safety standards.
  • Provide free access to a medical surveillance questionnaire template.

Next Steps

Participants will discuss the meeting with the organizations they represent.

  • Organizations will share their response to the USP Chapter 800 draft prior to submission to reinforce the shared points with a shared voice.
  • Approval of the joint position statement was obtained in February.
  • The group will design a plan to address consensus statements.

Meeting Attendees

External Guests

Melissa A. McDiarmid, MD, MPH, DABT (invited presenter)
Bona Benjamin, B.S.Pharm., Representing: American Society of Health-System Pharmacists (ASHP)
Patricia Kienle, RPh, MPA, FASHP, Representing: American Society of Health-System Pharmacists
Deborah Kamin, RN, PhD, Representing: American Society of Clinical Oncology (ASCO)
Steven K. Stranne, MD, JD, Representing: American Society of Clinical Oncology
Ryan Forrey, PharmD, MS, FASHP, Representing: Hematology/Oncology Pharmacists Association (HOPA)
Kristin Belderson, DNP, MS, RN, CPON, Representing: Association of Pediatric Hematology/Oncology Nurses (APHON)
Leah Ralph, Manager, Representing: Association of Community Cancer Centers (ACCC)

ONS Members

Martha Polovich, PhD, RN, AOCN®
Marlon Garzo Saria, MSN, RN, AOCNS®

ONS Staff

Michele R. McCorkle Dietz, RN, MSN, Executive Director, External Relations and Business Development
Michele Galioto, RN, MSN, Director, ONS Education
Kristine B. LeFebvre, MSN, RN, AOCN®, Oncology Clinical Specialist, Education Team
Alec Stone, MA, MPA, Director of Health Policy


Excellence in Radiation Therapy Nursing Award

Excellence in Radiation Therapy Nursing Award
2018 Award Recipient
Mary C. Corwin, BSN, RN, OCN®

To recognize and support excellence in radiation therapy nursing


A $500 award, a plaque, and travel reimbursement to attend the ONS Annual Congress

Eligibility Criteria 
The nominee must be an active ONS member who has been nominated by an ONS member. In addition, the nominee should
  • Be a registered professional nurse
  • Have at least two years of oncology nursing experience
  • Be a recognized expert in the field of radiation oncology (i.e., through publications, presentations, research, peer review)
  • Have made a significant contribution to one or more of the following related to radiation oncology: professional/patient education, clinical practice, and /or nursing research
  • Serve as a role model for other radiation oncology nurses.
Application Materials 
The following materials are required.
  • Nomination narrative statement
  • Nominee's resume or curriculum vitae
  • Nominee's personal statement
  • Two (2) letters of support
Important Notice About the Nomination Deadline 

ONS uses a vendor-supported online program for all award nomination applications. At exactly 5 pm ET on September 30, the application site will automatically shut down. Any applications that are not completed at this time will be terminated and will not be accepted. This deadline cannot be extended without prior authorization from the ONS Awards advisory panel and the ONS Board of Directors.

Scoring Criteria 
The scoring criteria for judging this nomination packet is as follows.
  • Clinical practice: Consistently demonstrates exemplary understanding and execution of the care of patients receiving radiation therapy.
  • Education: Shares knowledge of practice with students, peers, patients, and the community. (Examples include, but are not limited to, joint appointment(s), precepting students, staff development, program planning, patient teaching, outreach programs, and CNE programs).
  • Research: Demonstrates commitment to the advancement of practice through evidence of participation in research and research activities (possible activities include participation as data collector, site coordinator, study monitor, member of research team, co-investigator, principal investigator in a clinical research study related to radiation therapy. In addition, participation in research utilization activities, which promote research-based radiation oncology nursing practice).
  • Speaking: Regularly demonstrates expertise in field through public speaking and is recognized as an effective oral communicator.
  • Publication: Regularly contributes to the literature on issues regarding radiation therapy (includes articles in newsletters, journals, reports, video, multimedia, computer assisted instruction, or chapters in books).
  • ONS leadership: Participates in ONS activities at the local or national level. (Participation should include involvement at the local or national level, and includes membership on committees, holding office, or task force participation).
  • Professional practice: Provides leadership in activities, which advance the practice of radiation nursing (activities may include staff development, program development, patient teaching, or support groups. It might also include community outreach such as work with the ACS, Leukemia Society, or camps for cancer patients, or "survivors' day" activities. 
Submit Your Nomination 

Online Nominations are Closed 

Our ONS Award Nomination deadline was Saturday, September 30, 2017 at 5:00 PM EST. Our ONS Award Nominations will reopen in April 2018 through September 30, 2018.

Travel Information 

The recipient will receive travel reimbursement to attend the ONS Annual Congress. ONS will reimburse the award recipient for round-trip economy airfare to and from the recipient's home address to the Congress location, provided the recipient makes all travel arrangements through American Express Travel, ONS's official travel agency. Additionally, one (1) night's lodging will be permitted provided that the recipient makes the hotel arrangements through the ONS meetings department. Meals for a 24-hour period will be reimbursed, along with the reimbursement of certain ground transportation situations and parking, but there are limitations. Please contact for complete details about the travel reimbursement policy.

Leading Oncology Professional Societies Launch CancerLinQ Ambassadors Program

Leading Oncology Professional Societies Launch CancerLinQ® Ambassadors Program
Wednesday, March 8, 2017

Collaboration Will Enable On-the-Ground Engagement to CancerLinQ® Participants Nationwide

story and image

Inaugural CancerLinQ Oncology Leadership Council
ALEXANDRIA, Va. – CancerLinQ LLC, a wholly-owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), and the Oncology Nursing Society (ONS) announced today the formation of the CancerLinQ® Ambassadors Program. This new collaboration is a national practice engagement initiative that will provide on-the-ground support and guidance to CancerLinQ® participating practices on a regional basis. 
“As CancerLinQ continues to engage the community, the need to bring together physicians, nurses and the various professionals of the care team together to leverage our respective strengths is increasingly evident,” said Kevin Fitzpatrick, Chief Executive Officer of CancerLinQ LLC. “We are grateful to work with ONS to build on this commitment to care and enable every practice to get the most out of their use of the CancerLinQ® platform to ultimately benefit patients.”
Extending the reach and overall programmatic impact, oncology nurses will play a critical role in CancerLinQ’s successful adoption in all practice settings. With over 39,000 members and expertise in developing and implementing educational and oncology nurse consulting programs, ONS is well positioned to enhance the value add of CancerLinQ® through nurse involvement in a way that ultimately benefits cancer patients.
“Nurses play a critical role in not only the delivery of patient care, but also ensuring that information and data is utilized correctly for quality improvement,” said Brenda Nevidjon, PhD, RN, AOCN®, FAAN, Chief Executive Officer of ONS. “This collaboration with CancerLinQ allows nurses, physicians, and the entire health care team to better engage in practice and use technology to improve efficiency and provide the best care possible.”
The CancerLinQ® Ambassadors Program will launch in selected regions of the US with the long-term goal of expanding nationwide. ONS will recruit credentialed nurses from its membership with experience in quality improvement, informatics and technology to provide this guidance in the field. Ambassadors will visit practices on a regularly scheduled basis to answer questions and perform trainings for oncologists, oncology nurses and their practice staff, bringing back on-the-ground observations and feedback to augment CancerLinQ services and overall user experience. In addition, Ambassadors will work with practices to optimize the quality of the data they are sharing with CancerLinQ, disseminate best practices and provide coaching on how to integrate the platform into their workflow within their care team model. 
The collaboration with ONS is one of many that CancerLinQ is pursuing with a coalition of partners and thought leaders, including government agencies, medical specialty societies and life sciences companies. The American Society of Radiation Oncology (ASTRO) and Cancer Informatics for Cancer Centers (CI4CC) have recently joined forces with CancerLinQ and in November, AstraZeneca became a founding enterprise partner with CancerLinQ Discovery™. Through all these efforts, CancerLinQ hopes to receive guidance and gain insights that can improve quality and efficiency of the cancer care delivery system.
CancerLinQ is a powerful database—created by oncologists for oncologists—made up of vast amounts of usable, searchable, real-world cancer information. This big data initiative will allow users to see trends among millions of patients by analyzing cancer patient medical records, uncovering patterns that can improve patient care, and enabling the entire health care team to compare their care against that of their peers and recommended guidelines. 
CancerLinQ is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD, and Susan M. DaSilva; and Susan G. Komen®.
CancerLinQ® is a project of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ, please visit
# # #
About ASCO
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.
About CancerLinQ LLC
CancerLinQ LLC is a subsidiary of American Society of Clinical Oncology, Inc. established for the development and operation of the CancerLinQ® initiative. CancerLinQ is a health information technology platform aimed at enhancing and improving the understanding and treatment of cancer. To learn more, visit
About ONS
ONS is a professional association of more than 39,000 members committed to promoting excellence in oncology nursing and the transformation of cancer care. Since 1975, ONS has provided a professional community for oncology nurses, developed evidence-based education programs and treatment information, and advocated for patient care, all in an effort to improve quality of life and outcomes for patients with cancer and their families. Learn more at
Aaron Tallent
Aaron Borchert